Tag Archives: kite

Kite Pharma Down On Death Rumor, Juno Patent Dispute

Biotech stock Kite Pharma (KITE) continued to slide Friday after dropping 9% Thursday, and Cowen & Co. analyst Eric Schmidt thinks he knows why. “Recall that Kite is enrolling six patients in the Phase I portion of KTE-C19’s Phase I/II trial in refractory diffuse large B-cell lymphoma (DLBCL),” Schmidt wrote in a research note late Thursday. “Kite shares traded down today and based on our conversations with investors throughout the day, we believe

Kite Pharma, Bluebird Bio Team Up To Fight HPV

Biotechs Kite Pharma (KITE) and Bluebird Bio (BLUE) announced Monday that they’re collaborating on a new treatment for human papillomavirus (HPV), sending both stocks rising. The two companies plan to combine Kite’s expertise with T cell receptors (TCRs), components of cells that regulate the immune response, with Bluebird’s capabilities in gene editing and lentiviruses (harmless viruses that deliver gene therapies). They’re targeting HPV type 16,

Can CAR-T Therapy Live Up To The Biotech IPO Hype?

Biotech investors always seem to be looking for the next big thing. These days, many are going under the hood of the CAR-T. CAR-T is short for chimeric antigen receptor T-cell therapy, a version of immunotherapy, which deploys the patient’s own immune system to fight cancer. First developed in academic labs, CAR-T therapies have been picked up by big pharma Novartis (NVS) as well as a number of small startups. Kite Pharma (KITE), Bluebird Bio